Innovating targeting
Philogen is a fully integrated Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange. Our mission is to innovate the treatment of cancer and other serious conditions through targeted drugs.
One integrated company, from discovery to clinical development.
The Philogen Group integrates target discovery, ligand identification, prototype development, preclinical evaluation, in-house GMP manufacturing and clinical development to registration.
Discovery
The Philogen Group identifies accessible disease targets and discovers antibodies and small organic ligands.
Preclinical development
Targeting ligands are coupled with bioactive payloads to generate innovative targeted drugs which are tested in preclinical models.
In-house GMP manufacturing
Philogen manufactures its own products in its GMP facilities and offers manufacturing collaborations.
Clinical development
Philogen runs and manages clinical trials in-house across all stages, from Phase I through Phase III.
A targeted approach.
Philogen improves localization at the disease site through antibodies and small organic ligands.
Conventional therapeutic agents distribute throughout the body and may harm healthy organs. Philogen develops targeted solutions to act only at the site of disease.
Two product classes across clinical stages.
A clinical and preclinical pipeline built from antibody-cytokine fusions and small-molecule therapeutics.
Antibody-cytokine fusions
Fully human antibody-cytokine fusion proteins designed to localise cytokines at the disease site.
Small-molecule therapeutics
Small organic ligands coupled to cytotoxic drugs, radionuclides, immunomodulators or universal CAR-T adaptors.
Clinical trial activity
- 21Clinical trials
- 5Phase I
- 13Phase II
- 3Phase III